Exact Sciences Announces First-Quarter 2024 Results.

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has announced its first-quarter 2024 results. The company generated revenue of $638 million for the quarter, compared to $602 million for the same period in 2023. The increase in revenue was attributed to the delivery of over a million Cologuard and Oncotype DX test results to patients, as well as advancements in their pipeline of cancer diagnostics. The company aims to expand its portfolio globally and continue its mission to help eradicate cancer. [Extracted from the article]